Cerca una sperimentazione clinica
Altra/e opzione/i di ricerca
56 Risultato/i
Sperimentazione in fase di reclutamento
= 
; Sperimentazione in corso
= 
; Sperimentazione conclusa
= 
; Finanziato da un ente associato a IRDiRC = 
; Membro di una ERN = 
Sperimentazioni cliniche nazionali
REGNO UNITO; GRAN BRETAGNA
Cambridgeshire
CAMBRIDGE
APRIL: Safety of Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease (a feasibility trial)
Addenbrooke's Hospital
Addenbrookes Hospital
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
RBHIPF004 - A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
National Heart and Lung Institute, Imperial College, Royal Brompton Campus
Interstitial Lung Disease Unit
SVIZZERA
Suisse Alémanique
ZÜRICH
Prospective Assessment of MRI for Morphological and Functional Imaging in the Thorax
Universitätsspital Zürich
Institut für diagnostische und interventionelle Radiologie
AUSTRIA
WIEN
WIEN
HCQ4Surfdefect: Hydroxychloroquine (HCQ) in pediatric ILD (interstitial lung disease) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Pädiatrische Pulmologie, Allergologie und Endokrinologie
AUSTRIA
WIEN
WIEN
GOOD-IDES: An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Nephrologie und Dialyse
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Service de Pneumologie
BELGIO
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis - BE
Cliniques universitaires Saint-Luc - UCLouvain
Service de pneumologie
GERMANIA
Bayern
MÜNCHEN
chILD-EU_EAA: Stop exogenous allergic alveolitis in childhood (StopEAA) - European prospective, multicentre, randomized, double-blind, placebo controlled trial to implement a procedure for everyday care of Exogenous Allergic Alveolitis (Phase II)
Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital
Christiane Herzog Ambulanz
AUSTRALIA
Victoria
ADDRESS: NOT PROVIDED - AU
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -AU
Institution: Information not provided - AU
AUSTRIA
STEIERMARK
GRAZ
ANCA_CGM: Influence of once vs twice daily corticosteroid administration on glycemia assessed by continuous glucose monitoring in patients with ANCA vasculitis (phase 4)
Medizinische Universität Graz
Klinische Abteilung für Nephrologie
BULGARIA
South-West region
SOFIA
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - BG -
University Hospital Alexandrovska
Clinic of Hematology
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
MASTER-ANCA: Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical Trial.
Institution: Information not provided - FR
FRANCIA
ILE-DE-FRANCE
PARIS
PEXIVAS: Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis. An International Randomised Controlled Trial (phase III) - FR
AP-HP.Centre - Université de Paris - Hôpital Cochin
Unité fonctionnelle de Médecine interne et centre de référence maladies rares
GERMANIA
Nordrhein-Westfalen
MÜNSTER
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study - DE
Universitätsklinikum Münster
Centrum für seltene Erkrankungen (ZSE) Münster
ISRAELE
ISRAEL
PETAH TIKVA
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - IL -
Rabin Medical Center - Beilinson Hospital
Recanati Genetic Institute
ITALIA
CAMPANIA
NAPOLI
Valutazione dell'efficacia e del trattamento con Miglustat in pazienti affetti da malattia di Niemann-Pick di tipo c
Azienda Ospedaliera Universitaria "Federico II"
Laboratorio Dipartimento di Pediatria
ITALIA
FRIULI VENEZIA GIULIA
UDINE
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - IT -
Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" di Udine
Centro di Coordinamento Regionale per le Malattie Rare
ITALIA
PUGLIA
BARI
Terapia combinata della crioglobulinemia mista HCV-correlata con Interferone-alpha pegilato, ribavirina e rituximab
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Unità di Epatologia - Sezione di Medicina Interna e Oncologia Clinica
LIBANO
Beyrouth
BEIRUT
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - LB -
Hôtel-Dieu de France, Université Saint-Joseph
Oncology & Hematology
REGNO UNITO; GRAN BRETAGNA
Cambridgeshire
CAMBRIDGE
Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS
Addenbrooke's Hospital
Addenbrookes Hospital
REGNO UNITO; GRAN BRETAGNA
Greater London
ADDRESS: NOT PROVIDED - GB
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -GB
Institution: Information not provided - GB
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis-GB
Imperial College London, main campus
Imperial College London Headquarters
REGNO UNITO; GRAN BRETAGNA
Greater London
LONDON
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis-GB
Imperial College NHS Trust
REPUBBLICA CECA
Capital City Prague
PRAHA
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - CZ -
Vseobecna fakultni nemocnice a 1. lekarska fakulta UK
National Centre for Treatment of Gaucher Disease
SLOVACCHIA
Bratislavsky kraj
ADDRESS: NOT PROVIDED - SK
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study -SK
Institution: Information not provided - SK
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
ELIKIDS: Open label, Two Cohort (with and without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients with Gaucher Disease Type 1 and Type 3 -ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
TransportNPC: A Phase 3, Double blind, Randomized, Placebo controlled, Parallel group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol Cyclo (Hydroxypropyl beta cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann Pick Disease Type C1 -ES
Institution: Information not provided - ES
STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US
Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1): Potential Use of Antioxidant/Anti-inflammatory Medications
Institution: Information not provided - US
SVIZZERA
Suisse Alémanique
BERN
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study - CH
Universitätsspital Inselspital
University Hospital Inselspital
TUNISIA
TUNISIA
TUNIS
ENGAGE - A phase 3, randomized, double-blind, placebo-controlled, multi-center study confirming the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 - TN -
Hôpital La Rabta
Service de Pédiatrie
TURCHIA
TURKEY
IZMIR
ENCORE : A phase 3, randomized, multi-center, multi-national, open-label, active comparator study to evaluate the efficacy and safety of Genz-112638 in patients with Gaucher disease type 1 who have reached therapeutic goals with enzyme replacement therapy - TR -
Ege Üniversitesi
Department of Pediatrics - Cocuk asgligi ve Hastaliklari Anabilim Dali
FRANCIA
AUVERGNE-RHONE-ALPES
PIERRE-BENITE
MAINEPSAN Study: A Prospective Comparative Randomized Double-blind Placebo-controlled In-Parallel Groups Multicenter, Study to Evaluate the remission MAINtenance using Extended administration of Prednisone in Systemic anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis
CHU de Lyon HCL - GH Sud
Service de médecine interne et pathologie vasculaire
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy) - FR
Institution: Information not provided - FR
FRANCIA
ILE-DE-FRANCE
PARIS
CHUSPAN2 : Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Churg Strauss Syndrome Without Poor Prognosis Factors (Phase III)
AP-HP.Centre - Université de Paris - Hôpital Cochin
Unité fonctionnelle de Médecine interne et centre de référence maladies rares
GERMANIA
Baden-Württemberg
MANNHEIM
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Universitätsmedizin Mannheim
Universitätsklinikum Mannheim
GERMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy) -DE-
Institution: Information not provided - DE
GERMANIA
Berlin
BERLIN
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Charité - Universitätsmedizin Berlin
GERMANIA
Nordrhein-Westfalen
ESSEN
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Universitätsklinikum Essen
GERMANIA
Nordrhein-Westfalen
MÜNSTER
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Universitätsklinikum Münster
GERMANIA
Sachsen
DRESDEN
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
GERMANIA
Thüringen
JENA
A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) -DE-
Universitätsklinikum Jena
PAESI BASSI
Groningen
GRONINGEN
Prevention of Relapses in Proteinase 3 (PR3)-Anti-Neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
UMCG - Universitair Medisch Centrum Groningen
Afdeling Nefrologie
SPAGNA
Cataluña
BARCELONA
ABROGATE: Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non Severe, Granulomatosis with Polyangiitis (Wegener's) - ES
Hospital Clínic de Barcelona
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
OCEAN: A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy -ES
Institution: Information not provided - ES
STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US
Phase 1/2a Study of 2-Hydroxypropyl-Beta-Cyclodextrin Therapy for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
Institution: Information not provided - US
Sperimentazioni cliniche internazionali
CANADA
Alberta
MOUNTAIN VIEW
PAESI BASSI
Utrecht
ADDRESS: NOT PROVIDED - NL
A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease (Phase III) (Coordination)
Institution: Information not provided - NL
PAESI BASSI
Utrecht
ADDRESS: NOT PROVIDED - NL
EDGE: A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once Daily versus Twice Daily Dosing of Genz-112638 in Patients with Gaucher Disease Type 1 who have Demonstrated Clinical Stability on a Twice Daily Dose of Genz-112638
Institution: Information not provided - NL
PAESI BASSI
Zuid-Holland
LEIDEN
ENDURRANCE-1: Exploring durable remission with rituximab in ANCA associated vasculitis
LUMC - Leids Universitair Medisch Centrum
REGNO UNITO; GRAN BRETAGNA
Greater London
ADDRESS: NOT PROVIDED - GB
Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study
Institution: Information not provided - GB
REGNO UNITO; GRAN BRETAGNA
Oxfordshire
BEGBROKE
STATI UNITI
Massachusetts
CAMBRIDGE
STATI UNITI
Pennsylvania
PHILADELPHIA
PEXIVAS: Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial (phase III) (coordination)
Hospital of the University of Pennsylvania
Rheumatology Division
REGNO UNITO; GRAN BRETAGNA
Greater London
ADDRESS: NOT PROVIDED - GB
A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy (Phase III)
Institution: Information not provided - GB
REGNO UNITO; GRAN BRETAGNA
Greater London
ADDRESS: NOT PROVIDED - GB
Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy)
Institution: Information not provided - GB
SVIZZERA
Suisse Romande
ADDRESS: NOT PROVIDED - CH